Oncolytics Biotech, Inc. (TSE:ONC)’s stock price dropped 16.3% on Thursday . The company traded as low as C$1.25 and last traded at C$1.34, approximately 149,252 shares were traded during trading. An increase of 174% from the average daily volume of 54,528 shares. The stock had previously closed at C$1.60.
Separately, Roth Capital reiterated a “buy” rating on shares of Oncolytics Biotech in a research report on Wednesday, September 4th.
The stock’s 50-day moving average price is C$0.89 and its 200 day moving average price is C$1.63. The firm has a market capitalization of $36.01 million and a price-to-earnings ratio of -1.38. The company has a quick ratio of 2.76, a current ratio of 3.21 and a debt-to-equity ratio of 18.21.
Oncolytics Biotech Company Profile (TSE:ONC)
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Further Reading: What moving averages are used to define a golden cross?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.